EP2437603A4 - Verfahren zur behandlung von hepatischer enzephalopathie - Google Patents

Verfahren zur behandlung von hepatischer enzephalopathie

Info

Publication number
EP2437603A4
EP2437603A4 EP10797501A EP10797501A EP2437603A4 EP 2437603 A4 EP2437603 A4 EP 2437603A4 EP 10797501 A EP10797501 A EP 10797501A EP 10797501 A EP10797501 A EP 10797501A EP 2437603 A4 EP2437603 A4 EP 2437603A4
Authority
EP
European Patent Office
Prior art keywords
enzephalopathy
hepatic
treatment
hepatic enzephalopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP10797501A
Other languages
English (en)
French (fr)
Other versions
EP2437603A1 (de
Inventor
William Forbes
Enoch Bortey
Kunal Merchant
Audrey Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salix Pharmaceuticals Ltd
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/572,344 external-priority patent/US20100204173A1/en
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Priority to EP21202634.8A priority Critical patent/EP3964066A1/de
Publication of EP2437603A1 publication Critical patent/EP2437603A1/de
Publication of EP2437603A4 publication Critical patent/EP2437603A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP10797501A 2009-06-02 2010-06-02 Verfahren zur behandlung von hepatischer enzephalopathie Ceased EP2437603A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21202634.8A EP3964066A1 (de) 2009-06-02 2010-06-02 Verfahren zur behandlung von hepatischer enzephalopathie

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US18351309P 2009-06-02 2009-06-02
US12/572,344 US20100204173A1 (en) 2008-10-02 2009-10-02 Methods of treating hepatic encephalopathy
US26252509P 2009-11-18 2009-11-18
US30585410P 2010-02-18 2010-02-18
US30693510P 2010-02-22 2010-02-22
US30741710P 2010-02-23 2010-02-23
US31679610P 2010-03-23 2010-03-23
PCT/US2010/037131 WO2011005388A1 (en) 2009-06-02 2010-06-02 Methods of treating hepatic encephalopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP21202634.8A Division EP3964066A1 (de) 2009-06-02 2010-06-02 Verfahren zur behandlung von hepatischer enzephalopathie

Publications (2)

Publication Number Publication Date
EP2437603A1 EP2437603A1 (de) 2012-04-11
EP2437603A4 true EP2437603A4 (de) 2012-12-12

Family

ID=43429472

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10797501A Ceased EP2437603A4 (de) 2009-06-02 2010-06-02 Verfahren zur behandlung von hepatischer enzephalopathie
EP21202634.8A Pending EP3964066A1 (de) 2009-06-02 2010-06-02 Verfahren zur behandlung von hepatischer enzephalopathie

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP21202634.8A Pending EP3964066A1 (de) 2009-06-02 2010-06-02 Verfahren zur behandlung von hepatischer enzephalopathie

Country Status (9)

Country Link
EP (2) EP2437603A4 (de)
KR (3) KR20170036116A (de)
CN (1) CN102548408A (de)
AU (1) AU2010271070A1 (de)
BR (1) BRPI1010028A2 (de)
MX (1) MX2011012829A (de)
NZ (1) NZ596851A (de)
RU (1) RU2540513C2 (de)
WO (1) WO2011005388A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
EP2350096B1 (de) 2008-10-02 2019-12-11 Salix Pharmaceuticals, Ltd. Verfahren zur behandlung von hepatischer enzephalopathie
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
CN102625701A (zh) * 2009-06-15 2012-08-01 萨利克斯药品有限公司 对利福昔明系统暴露的调节
ES2986825T3 (es) 2011-11-02 2024-11-12 Salix Pharmaceuticals Inc Rifaximina para la repetición de tratamiento del síndrome del intestino irritable con predominio de diarrea
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
WO2017120533A1 (en) * 2016-01-08 2017-07-13 Colonaryconcepts Llc Food based delivery of therapeutic agent for treatment of hepatic encephalopathy
RU2618394C1 (ru) * 2016-02-24 2017-05-03 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт психического здоровья" Средство для защиты биомолекул плазмы крови от воздействия этанола
GB2607265A (en) * 2021-03-31 2022-12-07 The Flame Lily Holdings Ltd Outputting a notification

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040020A1 (en) * 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US20020028764A1 (en) * 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040020A1 (en) * 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BASS N ET AL: "93 RIFAXIMIN IS EFFECTIVE IN MAINTAINING REMISSION IN HEPATIC ENCEPHALOPATHY: RESULTS OF A LARGE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 50, 1 April 2009 (2009-04-01), pages S39, XP026495706, ISSN: 0168-8278, [retrieved on 20090401], DOI: 10.1016/S0168-8278(09)60095-7 *
JIANG Z D ET AL: "Rifaximin: In vitro and in vivo antibacterial activity - A review", CHEMOTHERAPY, vol. 51, 2005, pages 67 - 72, ISSN: 0009-3157 *
SALIX PHARMACEUTICALS ET AL: "Xifaxan Prescribing Information", 1 March 2008 (2008-03-01), pages 1 - 2, XP008139843, Retrieved from the Internet <URL:http://www.salix.com/assets/pdf/prescribe_into/xifaxanpi.pdf> *
See also references of WO2011005388A1 *
ZULLO ANGELO ET AL: "Rifaximin therapy and hepatic encephalopathy: Pros and cons.", WORLD JOURNAL OF GASTROINTESTINAL PHARMACOLOGY AND THERAPEUTICS 6 AUG 2012, vol. 3, no. 4, 6 August 2012 (2012-08-06), pages 62 - 67, ISSN: 2150-5349 *

Also Published As

Publication number Publication date
RU2540513C2 (ru) 2015-02-10
MX2011012829A (es) 2012-02-28
EP3964066A1 (de) 2022-03-09
KR20170036116A (ko) 2017-03-31
AU2010271070A1 (en) 2012-01-12
RU2011154138A (ru) 2013-07-20
CN102548408A (zh) 2012-07-04
KR20120025578A (ko) 2012-03-15
NZ596851A (en) 2013-10-25
WO2011005388A1 (en) 2011-01-13
EP2437603A1 (de) 2012-04-11
BRPI1010028A2 (pt) 2019-02-12
KR20190099100A (ko) 2019-08-23

Similar Documents

Publication Publication Date Title
EP2552415A4 (de) Verfahren zur behandlung von karzinomen
EP3251666C0 (de) Verfahren zur behandlung von neurotrauma
EP4144367C0 (de) Verfahren zur behandlung von durch cd47 vermittelter phagozytose
EP2437603A4 (de) Verfahren zur behandlung von hepatischer enzephalopathie
EP2613735A4 (de) Vorrichtungen und verfahren zur behandlung von gefässdefekten
EP2370593A4 (de) Verfahren zur behandlung von infektionen und tumoren
EP2459183A4 (de) Verfahren zur schmerzbehandlung
EP2410855A4 (de) Verfahren zur herstellung von alogliptin
EP3299380C0 (de) Verfahren zur aufreinigung von polypeptiden
EP2313146A4 (de) Vorrichtungen zur behandlung von vaskulärem aneurysma
DE202012013074U8 (de) Zusammensetzungen zur Behandlung von HCV
EP2396019A4 (de) Verfahren und zusammensetzungen zur hautbehandlung
DE112011100117A5 (de) Verfahren zur automatischen prävention von aquaplaning
EP2436978A4 (de) Trocknungseinheit und verfahren zur trocknung von festbrennstoffhaltigem wasser
EP2403503A4 (de) Verfahren zur behandlung von augenentzündungen
DE102010037160A8 (de) Verfahren zur Herstellung von Zahnersatz
EP2419399A4 (de) Zusammensetzungen und verfahren zur behandlung von entzündungen
EP2773212C0 (de) Verfahren und zusammensetzungen zur behandlung von autismus
EP2579936A4 (de) Magensonde zur behandlung von adipositas
EP2544703A4 (de) Verfahren zur behandlung von gefässentzündungserkrankungen
EP2560581A4 (de) Vorrichtungen und verfahren zur umformung von knöchelstrukturen
EP2559347A4 (de) Verfahren zur unterdrückung des geschmacks von cucurmin
EP2850195A4 (de) Verfahren und zusammensetzungen zur behandlung von amyloidablagerungen
DE102009012161B8 (de) Verfahren zur Herstellung von Polysaccharidderivaten
EP2257516A4 (de) Verfahren zur herstellung von cyclododecatrien und verfahren zur herstellung von laurolacton

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

A4 Supplementary search report drawn up and despatched

Effective date: 20121114

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20121108BHEP

Ipc: A01N 43/42 20060101AFI20121108BHEP

Ipc: A61K 31/437 20060101ALI20121108BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1168992

Country of ref document: HK

17Q First examination report despatched

Effective date: 20131111

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20211015

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230521